yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q33798442-2E533AC2-62A2-4E54-A266-36ECBEA2F718
Q33798442-2E533AC2-62A2-4E54-A266-36ECBEA2F718
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33798442-2E533AC2-62A2-4E54-A266-36ECBEA2F718
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.
P2860
Q33798442-2E533AC2-62A2-4E54-A266-36ECBEA2F718
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33798442-2E533AC2-62A2-4E54-A266-36ECBEA2F718
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
fc4edc161e88cfb7fed5d71800a34d0e00fdbdc8
P2860
A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.